Please assess the completion status of the following clinical trial:

Trial Title: Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years.~2. Able to give written, informed consent~3. Structural heart disease.~4. Implanted and normally functioning ICD or undergoing ICD implant at index admission.~5. Undergoing initial radiofrequency ablation procedure for sustained monomorphic VT.~6. Receiving a class III AADs prior to VT ablation.~7. No VT inducible at the end of VT ablation.~8. No VT inducible on non-invasive programmed stimulation following VT ablation.~Exclusion Criteria:~1. LV assist device in place~2. Decompensated heart failure and/or requiring continuous inotropic therapy and/or awaiting cardiac transplantation~3. Ongoing acute coronary syndrome.~4. Mechanical prosthetic aortic and mitral valves.~5. Pedunculated or mobile left ventricular thrombus.~6. Persistent VT at the end of index catheter ablation.~7. Absolute contraindications for class III AADs.~8. Participation in other trial.~9. VT induced on NIPS after VT ablation.~10. Another reason for continuation of class III AADs (i.e., atrial fibrillation).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuation of antiarrhythmic drugs (Type: EXPERIMENTAL): Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
- Discontinuation of antiarrhythmic drugs (Type: NO_INTERVENTION): Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).